Written and maintained by CASRAI Editorial Board
Published
On this page
Riegel v. Medtronic, Inc., 552 U.S. 312 (2008) is the landmark United States Supreme Court decision establishing that the express preemption clause of the Medical Device Amendments of 1976 (21 U.S.C. § 360k(a)) bars state common-law tort claims—including strict product liability, negligent design, negligent labeling, and breach of implied warranty—that challenge the safety or effectiveness of a Class III medical device that has received U.S. Food and Drug Administration (FDA) Premarket Approval (PMA). Alongside Medtronic, Inc. v. Lohr, 518 U.S. 470 (1996) and the learned intermediary doctrine, Riegel defines how federal regulatory pathways (510(k) vs. PMA) govern medical device and clinical AI product liability in the United States.
What Is Riegel v. Medtronic and How Does It Govern Healthcare Liability?
The case arose in 1996 when Charles Riegel underwent a percutaneous transluminal coronary angioplasty (PTCA) in which his physician inflated a Medtronic Evergreen Balloon Catheter—a Class III device that had received rigorous FDA Premarket Approval (PMA) in 1994 and supplemental PMA label approvals in 1995 and 1996—inside a diffusely diseased and heavily calcified right coronary artery (contrary to a contraindication on the FDA-approved device label) to a pressure of 10 atmospheres (above the label’s 8-atmosphere rated burst pressure). The catheter ruptured, requiring emergency coronary artery bypass surgery. Riegel and his wife sued Medtronic under New York common law alleging strict liability, breach of implied warranty, and negligence in the design, testing, inspection, distribution, labeling, marketing, and manufacture of the catheter.
Writing for an 8–1 majority on February 20, 2008, Justice Antonin Scalia affirmed summary judgment for Medtronic, holding that 21 U.S.C. § 360k(a) expressly preempted the Riegels’ state common-law tort claims because a jury verdict finding an FDA-approved PMA design or label defective under state law would impose state requirements “different from, or in addition to” the device-specific federal safety and effectiveness requirements mandated by the FDA’s PMA order.
What Statutory and Regulatory Requirements Govern Riegel Preemption?
Section 521(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), enacted by the Medical Device Amendments of 1976 and codified at 21 U.S.C. § 360k(a) (implemented by FDA regulation 21 CFR § 808.1(d)), states that no State or political subdivision of a State may establish or continue in effect with respect to a device intended for human use any requirement:
- Which is “different from, or in addition to,” any requirement applicable under the FD&C Act to the device, and
- Which relates to the safety or effectiveness of the device or to any other matter included in a requirement applicable to the device under the Act.
In Riegel, the Supreme Court established a mandatory two-step judicial inquiry for evaluating medical device express preemption:
- Step 1 — Did the Federal Government Establish Device-Specific Requirements? The Court contrasted the FDA 510(k) premarket notification pathway reviewed in Medtronic, Inc. v. Lohr (1996) with the Class III Premarket Approval (PMA) pathway (21 CFR Part 814). In Lohr, the Court held that 510(k) clearance evaluates only substantial equivalence to a pre-1976 predicate device—not standalone safety and effectiveness—and therefore does not impose device-specific federal design requirements. Conversely, PMA is a rigorous federal safety review (~1,200 hours of FDA review per application) that approves a specific design, manufacturing method, and exact product label; under 21 U.S.C. § 360e(d)(6)(A)(i), the manufacturer is forbidden from making any modification that affects safety or effectiveness without a PMA Supplement. Thus, PMA approval imposes device-specific federal requirements, satisfying Step 1.
- Step 2 — Are the Plaintiff’s State Common-Law Tort Claims “Different From, or in Addition to” Federal Requirements? The Court held that state common-law tort duties (negligence, strict liability, implied warranty) are state “requirements” within the meaning of § 360k(a). Because a state jury evaluates only the specific injured plaintiff without weighing the broader population benefit-risk trade-offs assessed by FDA CDRH experts, allowing a jury to hold that a PMA-approved device required a safer design or stronger warning label imposes state requirements “different from, or in addition to” the federal PMA mandate, satisfying Step 2 and triggering preemption.
| Regulatory Pathway | Controlling Supreme Court Precedent | Statutory Review Standard | Device-Specific Federal Requirements Under § 360k(a)? | Are Standard State Design/Labeling Tort Claims Preempted? |
|---|---|---|---|---|
| Premarket Approval (PMA) (21 CFR Part 814) & IDE Clinical Trials (21 CFR Part 812) | Riegel v. Medtronic, Inc., 552 U.S. 312 (2008) | Reasonable assurance of standalone safety and effectiveness | Yes — Exact design, specs, and labeling locked by FDA order | Yes — Expressly Preempted (Only narrow “parallel claims” survive) |
| 510(k) Clearance (21 CFR Part 807 Subpart E) | Medtronic, Inc. v. Lohr, 518 U.S. 470 (1996) | Substantial equivalence to a legally marketed predicate device | No — General controls only; no device-specific safety blueprint | No — Not Preempted (State strict liability & negligence claims proceed) |
| De Novo Classification (21 U.S.C. § 360c(f)(2)) | Lower federal court jurisprudence applying Lohr / Riegel | General & Special Controls for low-to-moderate risk novel devices | Generally treated closer to 510(k) unless specific special controls conflict | Generally Not Expressly Preempted under blanket PMA rules |
The “Narrow Gap”: Parallel Claims and the Interaction with Buckman
Crucially, Justice Scalia noted in Part IV of Riegel that § 360k(a) does not prevent a State from providing a damages remedy for claims premised on a violation of FDA regulations; in such cases, the state duties “parallel,” rather than add to, federal requirements. However, plaintiffs pleading a parallel claim against a PMA device manufacturer must thread a narrow legal needle between two Supreme Court doctrines:
- Avoiding Express Preemption (Riegel, 21 U.S.C. § 360k(a)): The plaintiff cannot claim the FDA-approved PMA design or label was itself defective; instead, the plaintiff must allege that the manufacturer deviated from its FDA-approved PMA specifications, failed to manufacture the unit in compliance with federal Quality Management System Regulations (21 CFR Part 820), or violated mandatory federal adverse-event reporting duties in a way that concurrently breached a traditional state-law duty.
- Avoiding Implied Preemption (Buckman Co. v. Plaintiffs’ Legal Committee, 531 U.S. 341 [2001], 21 U.S.C. § 337(a)): Under 21 U.S.C. § 337(a), all actions to enforce the FD&C Act must be brought by and in the name of the United States. Therefore, a private plaintiff cannot sue solely to enforce the FD&C Act or bring a standalone “fraud-on-the-FDA” claim; the claim must rest on pre-existing traditional state tort law whose breach happens to parallel a specific federal PMA violation.
How Does Riegel v. Medtronic Impact Clinical Research, EHRs, and Clinical AI / SaMD?
In contemporary clinical research and healthcare technology risk management (E&O vs. professional liability), Riegel creates three major operational consequences:
- Investigational Device Exemption (IDE) Clinical Trials (21 CFR Part 812): Federal circuit courts consistently extend Riegel express preemption to Class III investigational medical devices studied in human clinical trials under an FDA-approved Investigational Device Exemption (IDE), holding that FDA’s review and approval of the IDE clinical protocol, informed consent form, and device specifications constitute federal device-specific requirements under § 360k(a)—unless the investigator or sponsor violated the approved IDE protocol.
- Why Most FDA-Authorized Clinical AI / SaMD Lacks Riegel Preemption Shielding: Because over 95% of FDA-authorized artificial intelligence and machine learning (AI/ML) medical devices are cleared through the 510(k) pathway (or authorized via De Novo, which subsequently serves as a 510(k) predicate) rather than Class III Premarket Approval (PMA), virtually all commercial clinical AI software falls under Medtronic v. Lohr rather than Riegel v. Medtronic. Consequently, AI medical device vendors cannot rely on 21 U.S.C. § 360k(a) express federal preemption to dismiss state-law product liability and design-defect lawsuits.
- Off-Label Use Documentation in the EHR (21 U.S.C. § 396): In Riegel, the physician inflated the balloon catheter beyond the labeled pressure and in a contraindicated calcified vessel. While FD&C Act § 1006 (21 U.S.C. § 396) protects a physician’s authority to use an FDA-approved device off-label in the practice of medicine, Riegel shields the PMA manufacturer while leaving the treating clinician and hospital exposed to state medical malpractice claims if off-label deviation breaches the clinical standard of care.
Frequently Asked Questions
Why did Riegel’s lawsuit against Medtronic fail if the balloon catheter ruptured during surgery?
Because the Evergreen Balloon Catheter was a Class III device approved via FDA Premarket Approval (PMA), 21 U.S.C. § 360k(a) preempted state tort claims challenging its FDA-approved design and labeling, and the Riegels did not preserve a supported claim that Medtronic deviated from its FDA-approved manufacturing specifications.
Does FDA 510(k) clearance protect a medical device or AI vendor from state product liability lawsuits?
No. Under Medtronic, Inc. v. Lohr, 518 U.S. 470 (1996)—reaffirmed in Riegel—FDA 510(k) clearance establishes only substantial equivalence to a predicate device rather than federal device-specific safety requirements, leaving state common-law design-defect and failure-to-warn claims intact.
Did Congress ever pass the Medical Device Safety Act to overturn Riegel v. Medtronic?
No. Although bills titled the Medical Device Safety Act were introduced in Congress following the 2008 decision to amend 21 U.S.C. § 360k and restore state tort remedies against PMA devices, none was enacted into law, leaving Riegel v. Medtronic as binding Supreme Court precedent.







